Human Genome Epidemiology Literature Finder
Records 1 - 13 (of 13 Records) |
Query Trace: Diarrhea and NRAS[original query] |
---|
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Jan 18 (2): 555-67. Kirkwood John M, Bastholt Lars, Robert Caroline, Sosman Jeff, Larkin James, Hersey Peter, Middleton Mark, Cantarini Mireille, Zazulina Victoria, Kemsley Karin, Dummer Reinha |
Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013 Feb 24 (2): 412-9. André T, Blons H, Mabro M, Chibaudel B, Bachet J-B, Tournigand C, Bennamoun M, Artru P, Nguyen S, Ebenezer C, Aissat N, Cayre A, Penault-Llorca F, Laurent-Puig P, de Gramont A, |
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Apr 18 (7): 2056-65. Hayes D Neil, Lucas Amy S, Tanvetyanon Tawee, Krzyzanowska Monika K, Chung Christine H, Murphy Barbara A, Gilbert Jill, Mehra Ranee, Moore Dominic T, Sheikh Arif, Hoskins Janelle, Hayward Michele C, Zhao Ni, O'Connor Wendi, Weck Karen E, Cohen Roger B, Cohen Ezra E |
Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. Medical oncology (Northwood, London, England) 2018 May 35 (7): 101. Papaxoinis George, Kotoula Vassiliki, Giannoulatou Eleni, Koliou Georgia-Angeliki, Karavasilis Vasilios, Lakis Sotirios, Koureas Andreas, Bobos Mattheos, Chalaralambous Elpida, Daskalaki Emily, Chatzopoulos Kyriakos, Tsironis George, Pazarli Elisavet, Chrisafi Sofia, Samantas Epaminontas, Kaklamanos Ioannis G, Varthalitis Ioannis, Konstantara Athina, Syrigos Konstantinos N, Pentheroudakis George, Pectasides Dimitrios, Fountzilas Geor |
Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer. Cancer science 2018 Jun . Osumi Hiroki, Shinozaki Eiji, Mashima Tetsuo, Wakatsuki Takeru, Suenaga Mitsukuni, Ichimura Takashi, Ogura Mariko, Ota Yumiko, Nakayama Izuma, Takahari Daisuke, Chin Keisho, Miki Yoshio, Yamaguchi Kens |
A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research 2019 6 25 (18): 5475-5484. Kurzrock Razelle, Ball Douglas W, Zahurak Marianna L, Nelkin Barry D, Subbiah Vivek, Ahmed Shabina, O'Connor Ashley, Karunsena Enusha, Parkinson Rose M, Bishop Justin A, Ha Yoonji, Sharma Rajni, Gocke Christopher D, Zinner Ralph, Rudek Michelle A, Sherman Steven I, Azad Nilofer |
Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Apr . Wu Christina, Williams Terence M, Robb Ryan, Webb Amy, Wei Lai, Chen Wei, Mikhail Sameh, Ciombor Kristen K, Cardin Dana B, Timmers Cynthia, Krishna Somashekar G, Arnold Mark, Harzman Alan, Abdel-Misih Sherif, Roychowdhury Sameek, Bekaii-Saab Tanios, Wuthrick Ev |
Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. Clinical colorectal cancer 2021 Jul . Alshammari Kanan, Aung Kyaw L, Zhang Tong, Razak Albiruni R A, Serra Stefano, Stockley Tracy, Wang Lisa, Nguyen Jessica, Spreafico Anna, Hansen Aaron R, Zwir Dave, Siu Lillian L, Bedard Philippe |
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. JAMA oncology 2021 Aug . Martinelli Erika, Martini Giulia, Famiglietti Vincenzo, Troiani Teresa, Napolitano Stefania, Pietrantonio Filippo, Ciardiello Davide, Terminiello Marinella, Borrelli Carola, Vitiello Pietro Paolo, De Braud Filippo, Morano Federica, Avallone Antonio, Normanno Nicola, Nappi Anna, Maiello Evaristo, Latiano Tiziana, Falcone Alfredo, Cremolini Chiara, Rossini Daniele, Santabarbara Giuseppe, Pinto Carmine, Santini Daniele, Cardone Claudia, Zanaletti Nicoletta, Di Liello Alessandra, Renato Daniela, Esposito Lucia, Marrone Francesca, Ciardiello Fortuna |
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2022 3 28 (14): 3002-3010. Schuler Martin, Zimmer Lisa, Kim Kevin B, Sosman Jeffrey A, Ascierto Paolo A, Postow Michael A, De Vos Filip Y F L, van Herpen Carla M L, Carlino Matteo S, Johnson Douglas B, Berking Carola, Reddy Micaela B, Harney Allison S, Berlin Jordan D, Amaria Rodabe |
Coexistence of Chronic Myelomonocytic Leukemia and Ulcerative Colitis With Rapid Progression to Acute Myelomonocytic Leukemia: A Case Report. Cureus 2022 3 14 (2): e22422. Pelkey Lauren J, Graham David M, Zakem Michael H, Muza-Moons Michelle |
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO precision oncology 2022 11 6 e2200191. Klute Kelsey A, Rothe Michael, Garrett-Mayer Elizabeth, Mangat Pam K, Nazemzadeh Reza, Yost Kathleen J, Duvivier Herbert L, Ahn Eugene R, Cannon Timothy L, Alese Olatunji B, Krauss John C, Thota Ramya, Calfa Carmen J, Denlinger Crystal S, O'Lone Raegan, Halabi Susan, Grantham Gina N, Schilsky Richard |
First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations. BMC medicine 2023 1 21 (1): 2. Wang Xuan, Luo Zhiguo, Chen Jing, Chen Yu, Ji Dongmei, Fan Li, Chen Ling, Zhao Qian, Hu Pei, Sun Peng, Jia Zhongwei, Guo Jun, Si |
- Page last reviewed:Feb 1, 2024
- Content source: